Intensive chemotherapy combined with second- or third-generation tyrosine kinase inhibitors improves survival in patients ...

InnoCare Pharma’s tyrosine kinase 2 (TYK2) inhibitor has hit the main goals of a phase 2 trial in China, sustaining the ...

The ASC4FIRST trial explores asciminib for chronic myeloid leukaemia, but experts question its design and outcomes, ...

The new drug application resubmission of rivoceranib/camrelizumab in the first line in unresectable or metastatic ...

This article will describe the development of erlotinib, an EGFR tyrosine kinase inhibitor (EGFR-TKI), focusing on the clinical data reported in the treatment of NSCLC. Clorinda Schettino ...

Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib to standard tyrosine kinase inhibitor (TKI) treatment for patients with chronic-phase chronic myeloid leukemia ...

US-based biotechnology companies Exelixis and MSD have partnered to assess the potential of combining their respective cancer ...

The study found that the price tag for the second-generation Bruton tyrosine kinase inhibitor would need to be reduced by 30% ...

Furthest ahead in the pipeline is tolebrutinib, developed by Paris-based Sanofi to potentially treat SPMS, PPMS and relapsing forms of MS. The investigational agent is an oral central nervous system ...

HC Wainwright has initiated coverage on Alumis, highlighting the biopharmaceutical company's lead drug candidate, ESK-001.

Innocare Pharma Ltd.’s tyrosine kinase 2 (TYK2) inhibitor, ICP-488, met the primary endpoint in a phase II trial in Chinese patients with moderate to severe plaque psoriasis, and the results clear the ...

A comparison of the second-generation Bruton tyrosine kinase (BTK) inhibitor acalabrutinib to the first-generation ibrutinib ...